Becotatug Vedotin Clinical Trials
4 recruitingDrug
Phase 32Phase 21Phase 11
Showing 1–4 of 4 trials
Recruiting
Phase 2
A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
Adenoid Cystic CarcinomaSinonasal Carcinoma
Eye & ENT Hospital of Fudan University40 enrolled1 locationNCT07522879
Recruiting
Phase 1
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NeuroblastomaNasopharyngeal CarcinomaRhabdomyosarcoma+7 more
Sun Yat-sen University51 enrolled1 locationNCT07584499
Recruiting
Phase 3
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
Oligo-metastatic Cancer
Ming-Yuan Chen200 enrolled2 locationsNCT07481799
Recruiting
Phase 3
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Nasopharyngeal Carcinoma (NPC)
First Affiliated Hospital of Guangxi Medical University266 enrolled1 locationNCT07459296